An observational study in Adenosine Deaminase Deficiency and Severe Combined Immunodeficiency (SCID), sponsored by University of California, Los Angeles. Enrolling by invitation at 2 sites in 2 countries. Per ClinicalTrials.gov, last updated 2025-12-18.
Sponsored by University of California, Los Angeles · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Severe combined immunodeficiency due to adenosine deaminase deficiency with a site in United States — 2 open to participants now, 4 under way, none of them phase 3. Severe combined immunodeficiency due to adenosine deaminase deficiency · United States.
Among the 16 studies in Severe combined immunodeficiency due to adenosine deaminase deficiency with a site in United States, this one is one of 3 that started in 2019, is one of 7 observational ones, and was the 14th registered.
29 studies on the registry are indexed under Severe combined immunodeficiency due to adenosine deaminase deficiency; 4 are open to participants now.
Browse Severe combined immunodeficiency due to adenosine deaminase deficiency studies →2 of the 16 studies in Severe combined immunodeficiency due to adenosine deaminase deficiency with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States, Canada
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 2
First in 1990; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is close to the median of 76 across 13 observational studies indexed under Severe combined immunodeficiency due to adenosine deaminase deficiency.
Median enrollment 8 across the 9 interventional studies, 76 across the 7 observational. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 16 have an industry lead sponsor. The 9 most frequent:
University of California, Los Angeles is the lead sponsor of 1,172 studies on the registry; 195 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.
University of California, Los Angeles has 5 studies filed under Severe combined immunodeficiency due to adenosine deaminase deficiency — fewer than ten, so there is no comparison to draw.
2 of the studies in Severe combined immunodeficiency due to adenosine deaminase deficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT05432310University of California, Los AngelesGene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector | 2027-11-14 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Severe combined immunodeficiency due to adenosine deaminase deficiency with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This observational long-term follow-up study is designed to collect safety and efficacy data from ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS-ADA LV encoding for human adenosine deaminase (ADA) gene (EFS-ADA LV), as part of the OTL-101 clinical development program. No investigational medicinal product will be administered to these patients as part of the OTL-101-6 study.
The overall aim of this study is to record and evaluate long-term safety and efficacy data from ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS-ADA vector, as part of the UCL/A- ADA clinical development program. This will fulfil the requirements for the monitoring of delayed adverse events set by regulatory agencies for subjects treated with gene therapies.
The study will have the following specific objectives:
For any patients who completed their expected follow-up period before this study became available, outcome data will be retrospectively collected for the intervening period. From the first LTFU assessment onwards, prospective data will be gathered from the annual standard of care evaluations the patients will receive from the PI or their local healthcare professionals (HCPs).
Each patient, or their legal guardian, will be required to provide informed consent, which will define the objectives of this study, the expected duration of the patient's participation, as well as the data to be collected and the schedule of collection. It is anticipated that data will be collected annually to coincide with standard of care visits.
The study outcomes will be:
This observational LTFU study is open for enrollment to ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS-ADA lentiviral vector as part of the OTL-101 clinical development program. Patients treated in clinical trials as part of IND #15440, study OTL-101-5 (EudraCT No 2017-001275-23) or study 10-MI-29 (EudraCT No 2010-024253-36), as well as in Expanded Access or Compassionate Use Programs, will be eligible for enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A patient is eligible for enrollment in the study if all of the following criteria are met:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)
Overall Survival
Establishing efficacy through overall survival
Time frame: 15 years post-treatment
Event-Free Survival
Establishing efficacy through event-free survival
Time frame: 15 years post-treatment
Incidence of Adverse Events
Long-Term Safety incidence of AEs and SAEs
Time frame: 15 years post-treatment
Plan to share: No
Started Sep 2019 (actual). Primary completion is estimated for Aug 2040, 251 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Severe combined immunodeficiency due to adenosine deaminase deficiency →
University of California, Los Angeles →